Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)

Publication | Closed Access

DOI

Citations

References

2021

Year

Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, Yusuke Nakano, Koichi Azuma, Masahide Oki, Keiichi Ota, Hiroshige Yoshioka, Tomohiro Sakamoto, Nobuyuki Yamamoto,

Clinical Lung Cancer

L858r MutationMedicineImmunologyPathologyCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerMolecular OncologyPreviously Untreated Advanced